[1]陈晓明,程永德.中期肝癌TACE之争论与研究现状[J].介入放射学杂志,2021,30(08):751-755.
　CHEN Xiaoming,CHENG Yongde..Disputes and research status about transcatheter arterial chemoembolization for intermediate stage hepatocellular carcinoma[J].journal interventional radiology,2021,30(08):751-755.
点击复制

中期肝癌TACE之争论与研究现状()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年08
页码:
751-755
栏目:
专论
出版日期:
2021-08-25

文章信息/Info

Title:
Disputes and research status about transcatheter arterial chemoembolization for intermediate stage hepatocellular carcinoma
作者:
陈晓明;  程永德
Author(s):
CHEN Xiaoming;  CHENG Yongde.
Intervention Section of Oncology Center, Guangdong Provincial People’s Hospital, Guangdong Provincial Academy of Medical Sciences, Guangzhou, Guangdong Province 510080, China
关键词:
【关键词】 肝细胞肝癌; 化疗性栓塞; 系统治疗; 经导管肝动脉灌注化疗
文献标志码:
A
摘要:
【摘要】 TACE长期以来一直是中期肝癌的标准治疗。但是，近2年来，TACE受到了来自系统治疗和经导管肝动脉灌注化疗（HAIC）的影响。在如何面对靶向治疗和免疫治疗时代，中期肝癌治疗决策的定位，TACE在中期肝癌治疗中的重要作用，以及面对系统治疗和HAIC的机遇，本文从循证医学的角度，阐述上述问题。

参考文献/References:

［1］ Kudo M， Han KH， Ye SL， et al. A Changing paradigm for the treatment of intermediate- stage hepatocellular carcinoma：Asia- Pacific Primary Liver Cancer Expert Consensus Statements［J］. Liver Cancer， 2020， 9： 245-260.
［2］ Prince D， Liu K， Xu W， et al. Management of patients with intermediate stage hepatocellular carcinoma［J］. Ther Adv Med Oncol， 2020， 12： 1758835920970840.
［3］ Zuo MX， Huang JH. The history of interventional therapy for liver cancer in China［J］. J Intervent Med， 2018， 1： 70-76.
［4］ Kudo M， Ueshima K， Chan S， et al. Lenvatinib as an initial treatment in patients with intermediate- stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function： a proof- of- concept study［J］. Cancers（Basel）， 2019，11：1084.
［5］ Yamakado K， Hirota S. Sub- classification of intermediate- stage （Barcelona Clinic Liver Cancer stage- B） hepatocellular carcinomas［J］. World J Gastroenterol， 2015， 21： 10604-10608.
［6］ Shimose S， Kawaguchi T， Tanaka M， et al. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemo-embolization： a multicenter cohort study using data mining analysis［J］. Oncol Lett， 2020， 20： 2257-2265.
［7］ Shimose S， Iwamoto H， Tanaka M， et al. Alternating lenvatinib and trans- arterial therapy prolongs overall survival in patients with inter- mediate stage hepatocellular carcinoma： a propensity score matching study［J］. Cancers（Basel）， 2021， 13： 160.
［8］ Kudo M， Ueshima K， Ikeda M， et al. Randomised， multicentre prospective trial of transarterial chemoembolisation（TACE） plus sorafenib as compared with TACE alone in patients with hepato- cellular carcinoma： TACTICS trial［J］. Gut， 2020， 69： 1492-1501.
［9］ Long GB， Xiao CW， Zhao XY， et al. Effects of hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma： a meta-analysis［J］. Medicine（Baltimore）， 2020， 99： e20745.
［10］ Lyu N， Kong Y， Mu L， et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma［J］. J Hepatol， 2018， 69： 60- 69.
［11］ He M， Li Q， Zou R， et al. Sorafenib plus hepatic arterial infusion of oxaliplatin， fluorouracil， and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion： a randomized clinical trial［J］. JAMA Oncol， 2019， 5： 953-960.
［12］ Zhao Y， Lai JY， Liang RB， et al. Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma［J］. J Intervent Med， 2019， 2： 78-83.
［13］ He MK， Le Y， Li OJ， et al. Hepatic artery infusion chemothe- rapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma： a prospective non- randomized study［J］. Chin J Cancer， 2017， 36： 83- 88.
［14］ Tsai WL， Sun WC， Chen WC， et al. Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma［J］. Medicine， 2020， 99：32-39
［15］ Chang JM， Tzeng WS， Pan HB， et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study［J］. Cancer， 1994， 74： 2449-2453.
［16］ Lanza E， Donadon M， Poretti D， et al. Transarterial therapies for hepatocellular carcinoma［J］. Liver Cancer， 2016， 6： 27-33.
［17］ 吴沛宏，陈奇峰，李 旺． 肝细胞癌微创与多学科综合诊疗——2018广州共识［J］． 介入放射学杂志， 2019， 28：610- 624．

相似文献/References:

[1]吴安乐,颜志平,周康荣,等.单侧肺动脉化疗性栓塞术在转移性肺癌模型中的应用[J].介入放射学杂志,2007,(10):688.
　WU An-le,YAN Zhi-ping,ZHOU Kang-rong,et al.Application of unilateral pulmonary arterial chemoembolization in treating experimental pulmonary metastases[J].journal interventional radiology,2007,(08):688.
[2]邢桃红,牛焕章,周媛媛,等. TACE联合索拉非尼治疗23例中晚期肝细胞肝癌的护理[J].介入放射学杂志,2014,(05):449.
　XING Tao- hong,NIU Huan- zhang,ZHOU Yuan- yuan,et al. Nursing for patients with advanced hepatocellular carcinoma receiving transcatheter arterial chemoembolization combined with sorafenib： initial experience in 23 cases[J].journal interventional radiology,2014,(08):449.
[3]阿布都外力·吾布力卡斯穆,迪里木拉提·巴吾冬,任伟新. 巴塞罗那肝癌B期患者TACE治疗的预后及生存分析[J].介入放射学杂志,2014,(05):435.
　ABUDUWAILI Obulikasimu,DILMURAT Bawudun,REN Wei- xin.. Transcatheter arterial chemoembolization for the treatment of Barcelona stage B hepatocellular carcinoma： analysis of the prognosis and survival[J].journal interventional radiology,2014,(08):435.
[4]杨柏帅,施裕新,袁 敏,等.TACE治疗既往有肝功能衰竭史肝癌患者七例[J].介入放射学杂志,2014,(09):805.
　YANG Bo shuai,SHI Yu xin,YUAN Min,et al.TACE treatment for patients with inoperable hepatocellular carcinoma and hepatic failure history： initial experience in seven cases[J].journal interventional radiology,2014,(08):805.
[5]许 贇,沈 强,王 能,等.微波消融治疗＞70岁早期肝细胞肝癌患者效果分析[J].介入放射学杂志,2016,(04):332.
　XU Yun,SHEN Qiang,WANG Neng,et al.Effect analysis of microwave ablation therapy for early hepatocellular carcinoma in patients over 70 years old[J].journal interventional radiology,2016,(08):332.
[6]杨柏帅,施裕新,袁 敏,等.终末期肾衰竭肝癌患者TACE术中应用洛铂治疗3例[J].介入放射学杂志,2016,(05):381.
　YANG Bo- shuai,SHI Yu- xin,YUAN Min,et al.Transcatheter arterial chemoembolization using lobaplatin and lipiodol for the treatment of hepatocellular carcinoma associated with end- stage renal failure： report of three cases[J].journal interventional radiology,2016,(08):381.
[7]吴志远,丁晓毅,黄 蔚,等.门脉粒子支架联合载药微球栓塞治疗肝癌7例[J].介入放射学杂志,2017,(02):161.
　WU Zhiyuan,DING Xiaoyi,HUANG Wei,et al.Portal 125I seed stent implantation combined with drug-loaded microsphere embolization for the treatment of HCC： initial results in 7 patients[J].journal interventional radiology,2017,(08):161.
[8]王 燕,王茂强,段 峰.索拉非尼治疗中晚期肝癌预后因素分析[J].介入放射学杂志,2017,(03):258.
　WANG Yan,WANG Maoqiang,DUAN Feng.Prognostic factor analysis of moderate- advanced hepatocellular carcinoma treated with sorafenib [J].journal interventional radiology,2017,(08):258.
[9]余天柱,罗剑钧,颜志平.血管内近程放疗与序贯三维适形放疗治疗门静脉主干癌栓的疗效对比 [J].介入放射学杂志,2017,(09):787.
　YU Tianzhu,LUO Jianjun,YAN Zhiping.Endovascular brachytherapy vs. sequential three- dimensional conformal radiotherapy for the treatment of main portal vein tumor thrombus： a comparative study[J].journal interventional radiology,2017,(08):787.
[10]贾中芝,顾晓诚,蒋国民.门静脉癌栓分型对肝细胞性肝癌治疗方法的选择及患者预后的影响 [J].介入放射学杂志,2017,(10):944.
　JIA Zhongzhi,GU Xiaocheng,JIANG Guomin.The application of portal vein tumor thrombus classification in selecting therapeutic method for HCC patients and in estimating the prognosis[J].journal interventional radiology,2017,(08):944.

备注/Memo

备注/Memo:
（收稿日期：2021-06-17）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2021-08-18